Terns Pharmaceuticals Inc (TERN)
5.79
+0.08
(+1.40%)
USD |
NASDAQ |
Nov 22, 16:00
5.79
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals Enterprise Value: 112.22M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 112.22M |
| November 20, 2024 | 102.88M |
| November 19, 2024 | 129.21M |
| November 18, 2024 | 111.37M |
| November 15, 2024 | 151.30M |
| November 14, 2024 | 183.57M |
| November 13, 2024 | 203.11M |
| November 12, 2024 | 236.23M |
| November 11, 2024 | 260.87M |
| November 08, 2024 | 247.28M |
| November 07, 2024 | 226.74M |
| November 06, 2024 | 242.02M |
| November 05, 2024 | 236.08M |
| November 04, 2024 | 230.13M |
| November 01, 2024 | 216.55M |
| October 31, 2024 | 209.75M |
| October 30, 2024 | 212.30M |
| October 29, 2024 | 211.45M |
| October 28, 2024 | 180.03M |
| October 25, 2024 | 193.62M |
| October 24, 2024 | 200.41M |
| October 23, 2024 | 220.79M |
| October 22, 2024 | 264.10M |
| October 21, 2024 | 242.02M |
| October 18, 2024 | 256.46M |
| Date | Value |
|---|---|
| October 17, 2024 | 264.10M |
| October 16, 2024 | 276.84M |
| October 15, 2024 | 272.59M |
| October 14, 2024 | 274.29M |
| October 11, 2024 | 278.54M |
| October 10, 2024 | 256.03M |
| October 09, 2024 | 296.37M |
| October 08, 2024 | 290.42M |
| October 07, 2024 | 293.82M |
| October 04, 2024 | 329.49M |
| October 03, 2024 | 323.54M |
| October 02, 2024 | 323.54M |
| October 01, 2024 | 315.05M |
| September 30, 2024 | 335.43M |
| September 27, 2024 | 496.63M |
| September 26, 2024 | 521.96M |
| September 25, 2024 | 555.74M |
| September 24, 2024 | 586.13M |
| September 23, 2024 | 596.27M |
| September 20, 2024 | 620.75M |
| September 19, 2024 | 622.44M |
| September 18, 2024 | 636.79M |
| September 17, 2024 | 587.82M |
| September 16, 2024 | 569.25M |
| September 13, 2024 | 530.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-113.35M
Minimum
May 11 2022
808.72M
Maximum
Mar 19 2021
146.87M
Average
111.80M
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 739.59B |
| Viking Therapeutics Inc | 4.823B |
| Biomarin Pharmaceutical Inc | 11.76B |
| Elite Pharmaceuticals Inc | 657.76M |
| Verrica Pharmaceuticals Inc | 65.49M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.94M |
| Total Expenses (Quarterly) | 24.94M |
| EPS Diluted (Quarterly) | -0.28 |
| Earnings Yield | -20.38% |